The IMMUNOBIOGRAM® (IMBG) is a unique In Vitro Diagnostic (IVD) immunoassay offers a personalized comparative evaluation of the patient´s sensitivity/resistance profile to a panel of the most commonly used immunosuppressive drugs (IS) in clinical practice. The IMMUNOBIOGRAM® allows physicians to predict and monitor the response of patients‘ immune system cells to a specific IS. These cells are the target of all approved immunosuppressant therapies and are linked to drug efficacy.

The IMMUNOBIOGRAM® is a combination of a biotechnological KIT, and a software to produce meaningful results and elaborate reports. There is no other product providing similar information.

The  IMMUNOBIOGRAM® in Kidney Transplantation is ready for commercialization, and the Technology will be stepwise adapted and validated for other autoimmune diseases.


For the Physician

The IMMUNOBIOGRAM® provides information that will help physicians to personalize the immunosuppressive therapy in patients with inflammatory diseases, and help them to take informed decisions to select the most adequate immunosuppressive drugs (IS) for each patient to improve clinical outcomes.

For the Patient

In patients with renal transplant, an individualized immunosuppression regimen based on the patients´ immune cells response to IS can contribute notably to decrease graft rejection rates and to avoid the appearance of severe adverse events like metabolic disorders, opportunistic infections or malignancies.

For Health Care providers

The use of the IMBG would entail a:

  • potential risk reduction of graft failure, with costs savings of € 20,279 (95% CI € 17,512-23,105)  per high-risk transplanted patient in 5 years.
  • potential reduction in the AE rate that would generate savings per non-high risk patient in 5 years of € 3,328 (95% CI € 451-7,957).


It is a simple process for the patient and for the physician. From the patient it is required a 10 ml peripheral blood sample, and the physician can request the IMMUNOBIOGRAM®, along with other tests, during the routinely follow-up visits.

The clinical lab perform the test, raw data is sent to Biohope, and the patient´s report is sent back to the physician.